BOSTON – A nationwide coalition of attorneys general, including Massachusetts AG Andrea Joy Campbell, secured an agreement with eight drug makers for about $720 million. AG Campbell expects Massachusetts to receive $17 million from the settlement.
The companies, the total each agreed to pay, and the expected portion to Massachusetts are:
- Mylan (now part of Viatris): $284,447,916 paid over nine years (up to $6.7 million to Massachusetts)
- Hikma: $95,818,293 paid over one to four years (up to $2.4 million to Massachusetts)
- Amneal: $71,751,010 paid over 10 years (up to $3.1 million to Massachusetts)
- Apotex: $63,682,369 paid in a single year (up to $1.4 million to Massachusetts)
- Indivior: $38,022,450 paid over four years (up to $1.7 million to Massachusetts)
- Sun: $30,992,087 paid over one to four years (up to $700,000 to Massachusetts)
- Alvogen: $18,680,162 paid in a single year (up to $400,000 to Massachusetts)
- Zydus: $14,859,220 paid in a single year (up to 300,000 to Massachusetts)
Seven of these companies are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders.
Indivior agreed not to manufacture or sell opioid products for the next 10 years, but will continue marketing and selling medication to treat opioid use disorder…